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Aerobic glycolysis has been the most important hypothesis in cancer metabolism. It seems to be related to increased bioenergetic and 
biosynthetic needs in rapidly proliferating cancer cells. To this end, F-18 fluorodeoxyglucose (FDG), a glucose analog, became widely 
popular for the detection of malignancies combined with positron emission tomography/computed tomography (PET/CT). Although the 
potential roles of FDG PET/CT in primary tumor detection are not fully established, it seems to have a limited sensitivity in detecting early 
gastric cancer and mainly signet ring or non-solid types of advanced gastric cancer. In evaluating lymph node metastases, the location of 
lymph nodes and the degree of FDG uptake in primary tumors appear to be important factors affecting the diagnostic accuracy of PET/
CT. In spite of the limited sensitivity, the high specificity of PET/CT for lymph node metastases may play an important role in changing 
the extent of lymphadenectomy or reducing futile laparotomies. For peritoneal metastases, PET/CT seems to have a poorer sensitivity but 
a better specificity than CT. The roles of PET/CT in the evaluation of other distant metastases are yet to be known. Studies including pri-
mary tumors with low FDG uptake or peritoneal recurrence seem suffer from poorer diagnostic performance for the detection of recurrent 
gastric cancer. There are only a few reports using FDG PET/CT to predict response to neoadjuvant or adjuvant chemotherapy. A complete 
metabolic response seems to be predictive of more favorable prognosis.
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Introduction
In 1920s, Warburg et al.1 reported a phenomenon that cancer 
cells are dependent on glycolysis even in the presence of oxygen 
which is likely due to the impaired function of mitochondria. Since 
then, this Warburg effect has been the most important hypothesis 
in studying cancer metabolism and is considered as a seventh hall-
mark of human cancers.2 Aerobic glycolysis was originally attribut-
able to increased bioenergetic needs in rapidly proliferating cancer 
cells. Recently, biosynthetic aspect of aerobic glycolysis synthesizing 
macromolecules such as nucleotide, fatty acid, amino acid, etc. is 
under active investigation. Based on this phenomenon, F-18 fluo-
rodeoxyglucose (FDG), a glucose analog, became the most com-
monly used radiotracer for the detection of malignancies combined 
with positron emission tomography (PET)/computed tomography 
(CT). In this review, the potential roles of FDG PET/CT will be 
discussed in staging or restaging, monitoring therapeutic responses, 
and predicting patient clinical outcomes in gastric cancers.
Detection of Primary Tumors and  
Prediction of Prognosis
Imaging modalities such as CT provides exquisite anatomic 
details to determine the surgical resectability of gastric cancers 
whereas F-18 FDG PET/CT may have roles in predicting biologi-
cal aggressiveness and prognosis based on the metabolic activity of 
primary tumors. Until now, it has been reported that F-18 FDG 
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PET or PET/CT has 21% to 100% of sensitivity and 78% to 100% 
of specificity for detecting primary tumors.3-11 The wide ranges of 
sensitivity are associated with technical and histopathological fac-
tors affecting the visibility of primary tumors on PET/CT (Fig. 
1). There can be significant amounts of physiologic FDG uptake 
in the stomach which mimics pathology. Simple distention of the 
stomach using water reduces physiologic uptake and improves the 
diagnostic performance of PET/CT in detecting and localizing 
primary tumors, and assessing the degree of FDG uptake in gastric 
cancers.12-14 Other than technical issues, there are histopathologi-
cal factors affecting the PET/CT visibility of gastric cancers. The 
tumor size is important especially for early gastric cancer (EGC) 
since FDG uptake is underestimated due to a partial volume aver-
aging effect on PET/CT. Low FDG uptake is more often seen in 
signet ring cell and mucinous types of gastric cancer. Of the mac-
roscopic types, Borrmann’s type I has significantly higher FDG 
uptake than do the other 3 types. Borrmann’s type 4 seems to have 
the least FDG uptake in primary tumors. Of the microscopic types, 
intestinal type has more FDG uptake than diffuse type. Regarding 
the differentiation, low FDG uptake was reported in poorly differ-
entiated types, which is likely due to the low concentration of can-
cer cells in primary lesions.15 However, a wide spectrum of FDG 
uptake from low to intense is also seen in poorly differentiated 
adenocarcinomas. Other factors besides histologic differentiation 
seem important in determining FDG uptake in adenocarcinomas 
of poorly differentiated type.5 Overall, PET/CT has a limited sensi-
tivity in detecting EGC and some types of advanced gastric cancer 
(AGC) as discussed above.
One of the benefits on PET/CT is in the prediction of biological 
aggressiveness and/or patient prognosis on the basis of the meta-
bolic activity of primary tumors. There are controversial, limited 
data whether the degree of FDG uptake on PET/CT is predictive of 
patient prognosis.3,16-20 Some reported a longer survival in patients 
with negative PET than those with positive PET whereas oth-
ers could not find any difference in survival rate between patients 
with high FDG uptake and those with low FDG uptake. Studies by 
histopathological subtypes seem to give better information on the 
association between FDG uptake and patient prognosis.18,20 In our 
study assessing 41 patients with curative gastrectomy for advanced 
signet ring cell carcinoma, with a cutoff standardized uptake value 
(SUV) of 3.8, the high SUV group showed more aggressive tumor 
behavior than did the low SUV group.18 The high SUV group also 
had more postoperative recurrence, shorter relapse free survival, 
and lower 30 months cancer specific survival rates although SUV 
was not an independent predictor of overall survival.
TNM Staging 
Accurate staging is essential in selecting optimal management 
plan for the patients preoperatively. The role of PET/CT is limited 
in T staging of primary tumors due to its low spatial resolution 
preventing the evaluation of adjacent organ invasion. The presence 
Fig. 1. Histopathologic factors affecting fluorodeoxyglucose (FDG) uptake in advanced gastric cancers (AGCs). (A, B, C) AGC with intense FDG 
uptake (arrows) and intestinal growth pattern (H&E, ×100). (D, E, F) AGC with mild FDG uptake (arrows) and diffuse growth pattern (H&E, 
×100).
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of lymph node metastases is one of the most important prognostic 
factors in gastric cancer. N staging has been typically dependent on 
the size of lymph node on CT. However, the size criterion is insuf-
ficient to guide the optimal extent of lymphadenectomy. There are 
several papers showing limited sensitivity of FDG PET or PET/
CT in evaluating lymph node metastases in gastric cancer.5,7,11,21 The 
location of the lymph nodes and FDG uptake in primary tumors 
appear to have some impact on diagnostic performance of PET/
CT. Despite the high specificity, it is less sensitive than CT for de-
tecting perigastric lymph nodes. The spatial resolution of PET/CT 
may not be good enough to discriminate those perigastric lymph 
nodes from adjacent primary tumors. However, accurate staging of 
perigastric lymph node metastases may not be important since all 
AGC patients are to undergo at least D1 dissection. Unlike perigas-
tric lymph nodes, the determination of N2 or N3 group is of clini-
cal importance, as the extent of lymph node dissection or curative 
potential of surgery can be changed. So far, PET/CT show limited 
sensitivity of less than 50% in detecting metastases in N2 or N3 
group whereas it is highly specific (over 90% or higher) for N2 or 
N3 node metastases. Given the high specificity for N2 or N3 dis-
ease, PET/CT may play an important role in extending the degree 
of lymphadenectomy or reducing futile laparotomies. For N stag-
ing, PET/CT is considered to have similar diagnostic performance 
to contrast enhanced CT.11 Further studies are needed to evaluate 
additional benefit of PET/CT in detecting small lymph nodes in 
which CT cannot determine the presence of metastases.
Although there are not enough data yet, FDG PET seems lim-
ited in detecting peritoneal metastases.6,15 Lim et al.22 retrospectively 
compared FDG PET to contrast enhanced CT in 112 patients with 
histological confirmation for the absence or presence of peritoneal 
metastases. PET showed a poorer sensitivity of 35% but a better 
specificity of 99% than CT which had a sensitivity of 77% and a 
specificity of 92%. Studies are needed to see whether the degree of 
FDG uptake in primary tumors may affect the sensitivity of PET/
CT in detecting peritoneal metastases (Fig. 2). For the evaluation 
of other distant metastases including the liver, bone, lung, adrenal 
gland, or etc, the roles of PET/CT are yet to be known. A recent 
study reported that PET/CT detects occult metastases in about 10% 
of patients with AGC.23 They suggested PET/CT to be a compo-
nent of the standard staging algorithm for AGC due to reduced 
morbidity from fewer futile operations and lower patient care costs.
Detection of Recurrent Tumors
Common locations of recurrence after initial surgery include 
locoregional areas, peritoneum, extra-abdominal lymph nodes, and 
hematogenous spread to distant sites. Although contrast CT is most 
commonly used in detecting recurrence, its accuracy can be com-
promised by anatomical alterations related to postoperative chang-
es. PET/CT has shown inconsistent results in detecting recurrent 
gastric cancers.15,16,24-30 Primary tumors included in a study popula-
tion and location of recurrent tumors might have something to do 
with the contradictory results of PET/CT. Studies including more 
primary tumors with low FDG uptake or peritoneal recurrence 
seem to suffer from poorer diagnostic performance.16,29 In recent 
data comparing PET/CT with contrast CT, PET/CT was at least as 
sensitive and specific as contrast enhanced CT in the detection of 
recurrent gastric cancers except for peritoneal metastases.28,30 Gas-
tric distention using water is encouraged to improve the accuracy of 
PET in differentiating recurrent tumor from physiologic uptake in 
the remnant stomach although it is limited in the detection of those 
recurrent tumors with low FDG uptake.12
Therapeutic Response Evaluation
Neoadjuvant therapy has been increasingly used to reduce tumor 
stage, to plan the best surgical strategies, to test in vivo chemo-
sensitivity, and to improve overall survival in patients with various 
locally advanced cancers. Only those patients with a clinical and 
Fig. 2. Peritoneal seeding metastases with variable F-18 fluorodeoxy-
glucose (FDG) uptake on positron emission tomography/computed 
tomography. (A) Typical metastatic nodules with high FDG uptake 
(arrows) in the omentum. (B) Mild and diffuse FDG uptake (arrows) 
along the omentum.
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pathological response to neoadjuvant therapy may have a signifi-
cant survival benefit. Therefore, the early identification of respond-
ers from non-responders using clinical and/or imaging predictors 
seems to be essential. On CT, treatment response may be under-
estimated by treatment related changes such as fibrosis, necrosis, 
inflammation, and edema. Because changes in glucose metabolism 
can precede changes in morphology, FDG can be an early and 
sensitive pharmacodynamic marker of tumor response to treat-
ment. It largely represents viable tumor cell number and a reduction 
in FDG uptake may reflect the tumor cell killing rate. Other than 
FDG uptake remained after the completion of treatment, changes 
in FDG uptake soon after the initiation of treatment is also related 
to final patient outcomes (Fig. 3). The latter can provide earlier as-
sessment of treatment response in clinical trials as well as patient 
management.
For response evaluation, the results of FDG PET or PET/CT 
need to be correlated with tumor regression grades on histopatho-
logic specimen, tumor recurrence, or patient survival. In gastric 
cancer, there are only a few studies using PET to predict responses 
to neoadjuvant or adjuvant chemotherapy. Good correlations were 
reported between changes in FDG uptake early during the course 
of neoadjuvant chemotherapy and histopathological responses.31,32 A 
complete metabolic response on FDG PET seems to be predictive 
of more favorable prognosis. In adjuvant setting, some reported that 
either early metabolic response or lower primary tumor SUV can 
predict better clinical outcome in patients with AGC.17,33 
One of the limitations of FDG PET or PET/CT for response 
evaluation to neoadjuvant therapy is that FDG PET is not able to 
differentiate complete tumor response from microscopic residual 
tumor. Therefore, the decision on the extent of surgery cannot be 
made by FDG PET/CT alone. Of gastric cancers, certain histologic 
types may not show increased FDG which could make response 
evaluation difficult. Physiologic FDG uptake in the stomach without 
distention may underestimate tumor response to treatment. Besides 
these limitations, the best time to do posttreatment FDG PET/CT 
is still a matter of debate. Early assessment at mid-treatment seems 
to be useful in selecting responders from non-responders, modify-
ing subsequent treatment, and avoiding unnecessary side effects in 
non-responders. Lastly, the methodology in analyzing FDG uptake 
or changes in SUVs is yet to be standardized.
Conclusions
FDG PET/CT has a limited sensitivity in detecting EGC and 
mainly signet ring or non-solid types of AGC. Although it does not 
provide exquisite anatomic details to determine the surgical resect-
ability, it has potential roles in predicting biological aggressiveness 
and prognosis based on the metabolic activity of primary tumors. 
So far, there are controversial, limited data whether the degree of 
FDG uptake on PET/CT is predictive of patient prognosis. FDG 
PET/CT has limited sensitivity in evaluating lymph node metas-
tases. The location of lymph nodes and FDG uptake in primary 
Fig. 3. Changes in fluorodeoxyglucose 
(FDG) uptake of the primary tumors 
on positron emission tomography/
computed tomography (PET/CT) to 
neoadjuvant chemotherapy. (A, B) 
PET responder, FDG uptake in the 
primary tumor showing more than 
35% decreases in standardized uptake 
value (SUV) which is predictive of 
histopathological response and bet-
ter patient survival. (C, D) PET non-
responder, no remarkable changes in 
SUV in the primary tumor. 
Imaging of Gastric Cancer Metabolism Using 18 F-FDG PET/CT
5
tumors appear to be important factors affecting the diagnostic 
accuracy of PET/CT. Given the high specificity of PET/CT for 
lymph node metastases, it may play an important role in changing 
the extent of lymphadenectomy or reducing futile laparotomies. 
For the detection of peritoneal metastases, PET/CT seems to have 
a poorer sensitivity but a better specificity than CT. For the evalu-
ation of other distant metastases, the roles of PET/CT are yet to be 
known. PET/CT has shown inconsistent results in detecting recur-
rent gastric cancers. Studies including more primary tumors with 
low FDG uptake or peritoneal recurrence seem suffer from poorer 
diagnostic performance. There are only a few reports using FDG 
PET to predict response to neoadjuvant or adjuvant chemotherapy. 
A complete metabolic response on FDG PET seems to be predic-
tive of more favorable prognosis.
References
1. Warburg O, Wind F, Negelein E. The metabolism of tumors in 
the body. J Gen Physiol 1927;8:519-530.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next gen-
eration. Cell 2011;144:646-674.
3. Stahl A, Ott K, Weber WA, Becker K, Link T, Siewert JR, et al. 
FDG PET imaging of locally advanced gastric carcinomas: cor-
relation with endoscopic and histopathological findings. Eur J 
Nucl Med Mol Imaging 2003;30:288-295.
4. Mochiki E, Kuwano H, Katoh H, Asao T, Oriuchi N, Endo K. 
Evaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emis-
sion tomography for gastric cancer. World J Surg 2004;28:247-
253. 
5. Yun M, Lim JS, Noh SH, Hyung WJ, Cheong JH, Bong JK, 
et al. Lymph node staging of gastric cancer using (18)F-FDG 
PET: a comparison study with CT. J Nucl Med 2005;46:1582-
1588.
6. Chen J, Cheong JH, Yun MJ, Kim J, Lim JS, Hyung WJ, et 
al. Improvement in preoperative staging of gastric adeno-
carcinoma with positron emission tomography. Cancer 
2005;103:2383-2390.
7. Kim SK, Kang KW, Lee JS, Kim HK, Chang HJ, Choi JY, et al. 
Assessment of lymph node metastases using 18F-FDG PET 
in patients with advanced gastric cancer. Eur J Nucl Med Mol 
Imaging 2006;33:148-155.
8. Mukai K, Ishida Y, Okajima K, Isozaki H, Morimoto T, Nishi-
yama S. Usefulness of preoperative FDG-PET for detection of 
gastric cancer. Gastric Cancer 2006;9:192-196.
9. Herrmann K, Ott K, Buck AK, Lordick F, Wilhelm D, Sou-
vatzoglou M, et al. Imaging gastric cancer with PET and the 
radiotracers 18F-FLT and 18F-FDG: a comparative analysis. J 
Nucl Med 2007;48:1945-1950.
10. Kameyama R, Yamamoto Y, Izuishi K, Takebayashi R, Hagiike 
M, Murota M, et al. Detection of gastric cancer using 18F-FLT 
PET: comparison with 18F-FDG PET. Eur J Nucl Med Mol 
Imaging 2009;36:382-388. 
11. Kim EY, Lee WJ, Choi D, Lee SJ, Choi JY, Kim BT, et al. The 
value of PET/CT for preoperative staging of advanced gastric 
cancer: comparison with contrast-enhanced CT. Eur J Radiol 
2011;79:183-188.
12. Yun M, Choi HS, Yoo E, Bong JK, Ryu YH, Lee JD. The role 
of gastric distention in differentiating recurrent tumor from 
physiologic uptake in the remnant stomach on 18F-FDG PET. 
J Nucl Med 2005;46:953-957.
13. Kamimura K, Nagamachi S, Wakamatsu H, Fujita S, Nishii R, 
Umemura Y, et al. Role of gastric distention with additional 
water in differentiating locally advanced gastric carcinomas 
from physiological uptake in the stomach on 18F-fluoro-2-
deoxy-D-glucose PET. Nucl Med Commun 2009;30:431-439. 
14. Takahashi H, Ukawa K, Ohkawa N, Kato K, Hayashi Y, Yoshi-
moto K, et al. Significance of (18)F-2-deoxy-2-fluoro-glucose 
accumulation in the stomach on positron emission tomogra-
phy. Ann Nucl Med 2009;23:391-397. 
15. Yoshioka T, Yamaguchi K, Kubota K, Saginoya T, Yamazaki 
T, Ido T, et al. Evaluation of 18F-FDG PET in patients with 
advanced, metastatic, or recurrent gastric cancer. J Nucl Med 
2003;44:690-699.
16. De Potter T, Flamen P, Van Cutsem E, Penninckx F, Filez L, 
Bormans G, et al. Whole-body PET with FDG for the diagno-
sis of recurrent gastric cancer. Eur J Nucl Med Mol Imaging 
2002;29:525-529. 
17. Chung HW, Lee EJ, Cho YH, Yoon SY, So Y, Kim SY, et al. 
High FDG uptake in PET/CT predicts worse prognosis in 
patients with metastatic gastric adenocarcinoma. J Cancer Res 
Clin Oncol 2010;136:1929-1935.
18. Pak KH, Yun M, Cheong JH, Hyung WJ, Choi SH, Noh SH. 
Clinical implication of FDG-PET in advanced gastric cancer 
with signet ring cell histology. J Surg Oncol 2011;104:566-570.
19. Park JC, Lee JH, Cheoi K, Chung H, Yun MJ, Lee H, et al. Pre-
dictive value of pretreatment metabolic activity measured by 
fluorodeoxyglucose positron emission tomography in patients 
with metastatic advanced gastric cancer: the maximal SUV of 
Yun M
6
the stomach is a prognostic factor. Eur J Nucl Med Mol Imag-
ing 2012;39:1107-1116.
20. Lee JW, Lee SM, Lee MS, Shin HC. Role of ¹⁸F-FDG PET/CT 
in the prediction of gastric cancer recurrence after curative 
surgical resection. Eur J Nucl Med Mol Imaging 2012;39:1425-
1434.
21. Yang QM, Kawamura T, Itoh H, Bando E, Nemoto M, Akamo-
to S, et al. Is PET-CT suitable for predicting lymph node status 
for gastric cancer? Hepatogastroenterology 2008;55:782-785.
22. Lim JS, Kim MJ, Yun MJ, Oh YT, Kim JH, Hwang HS, et al. 
Comparison of CT and 18F-FDG pet for detecting peritoneal 
metastasis on the preoperative evaluation for gastric carci-
noma. Korean J Radiol 2006;7:249-256.
23. Smyth E, Schöder H, Strong VE, Capanu M, Kelsen DP, Coit 
DG, et al. A prospective evaluation of the utility of 2-de-
oxy-2-[(18) F]fluoro-D-glucose positron emission tomography 
and computed tomography in staging locally advanced gastric 
cancer. Cancer 2012;118:5481-5488. 
24. Jadvar H, Tatlidil R, Garcia AA, Conti PS. Evaluation of recur-
rent gastric malignancy with [F-18]-FDG positron emission 
tomography. Clin Radiol 2003;58:215-221.
25. Nakamoto Y, Togashi K, Kaneta T, Fukuda H, Nakajima K, 
Kitajima K, et al. Clinical value of whole-body FDG-PET for 
recurrent gastric cancer: a multicenter study. Jpn J Clin Oncol 
2009;39:297-302.
26. Park MJ, Lee WJ, Lim HK, Park KW, Choi JY, Kim BT. Detect-
ing recurrence of gastric cancer: the value of FDG PET/CT. 
Abdom Imaging 2009;34:441-447.
27. Sohn YJ, Jang JS, Choi SR, Kwon HC, Jung GJ, Kim MC, et al. 
Early detection of recurrence after endoscopic treatment for 
early gastric cancer. Scand J Gastroenterol 2009;44:1109-1114.
28. Sim SH, Kim YJ, Oh DY, Lee SH, Kim DW, Kang WJ, et al. The 
role of PET/CT in detection of gastric cancer recurrence. BMC 
Cancer 2009;9:73.
29. Lee JE, Hong SP, Ahn DH, Jeon TJ, Kang MK, Kwon CI, et 
al. The role of 18F-FDG PET/CT in the evaluation of gastric 
cancer recurrence after curative gastrectomy. Yonsei Med J 
2011;52:81-88.
30. Bilici A, Ustaalioglu BB, Seker M, Kefeli U, Canpolat N, Tekin-
soy B, et al. The role of ¹⁸F-FDG PET/CT in the assessment 
of suspected recurrent gastric cancer after initial surgical 
resection: can the results of FDG PET/CT influence patients' 
treatment decision making? Eur J Nucl Med Mol Imaging 
2011;38:64-73.
31. Ott K, Fink U, Becker K, Stahl A, Dittler HJ, Busch R, et al. 
Prediction of response to preoperative chemotherapy in gastric 
carcinoma by metabolic imaging: results of a prospective trial. 
J Clin Oncol 2003;21:4604-4610.
32. Ott K, Herrmann K, Lordick F, Wieder H, Weber WA, Becker 
K, et al. Early metabolic response evaluation by fluorine-18 flu-
orodeoxyglucose positron emission tomography allows in vivo 
testing of chemosensitivity in gastric cancer: long-term results 
of a prospective study. Clin Cancer Res 2008;14:2012-2018.
33. Di Fabio F, Pinto C, Rojas Llimpe FL, Fanti S, Castellucci P, 
Longobardi C, et al. The predictive value of 18F-FDG-PET 
early evaluation in patients with metastatic gastric adenocar-
cinoma treated with chemotherapy plus cetuximab. Gastric 
Cancer 2007;10:221-227. 
